Novel drug LCL768 Cuts Off Energy Supply to Head and Neck Cancer Cells in Promising preclinical Trials
Table of Contents
A new drug, LCL768, is showing significant promise in preclinical studies as a potential treatment for aggressive head and neck cancers. Researchers at MUSC Hollings Cancer center have discovered that the compound attacks cancer cells by disrupting their energy production, offering a perhaps safer and more effective choice to current therapies.
Targeting a Metabolic Weakness in Cancer
Head and neck squamous cell carcinoma, a cancer affecting cells lining the head and neck, is notoriously difficult to treat. The cancer is often resistant to standard treatments, frequently returns after initial remission, and can cause debilitating side effects due to its impact on both cancerous and healthy cells. The multidisciplinary research team, led by a senior official at Hollings, focused on exploiting a key vulnerability in these cancers: a deficiency in ceramide, a fat molecule crucial for healthy cell function.
“Many head and neck cancers are low in this helpful fat, which predicts poorer patient outcomes and contributes to the tumors’ aggressive growth,” explained a researcher involved in the study. To address this, the team developed LCL768, a synthetic form of ceramide.
How LCL768 Works: A dual Attack on Cancer Cells
LCL768’s effectiveness stems from a dual attack on cancer cells. first, the drug boosts ceramide levels, inducing metabolic stress. this stress, in turn, depletes fumarate, a key molecule in the Krebs cycle – the cell’s primary energy-generating pathway. This depletion was followed by clear signs of mitophagy and metabolic collapse, resulting in slowed tumor growth.
Notably, restoring fumarate levels almost completely reversed the drug’s inhibitory effects, causing the tumors to rapidly regrow. This finding underscores the importance of fumarate depletion in LCL768’s mechanism of action.
A Safer Alternative to Traditional Treatments?
A key advantage of LCL768 is its apparent selectivity for cancer cells. The study indicated that the drug had minimal impact on healthy tissues, suggesting it could offer a safer alternative to conventional treatments like chemotherapy and radiation.
“The drug hones in on a process cancer cells use to avoid normal cell death,” a researcher noted. “As healthy cells do not rely as heavily on these pathways, they are left mostly untouched.”
Looking Ahead: Clinical Trials on the Horizon
While still in the preclinical phase, the results are encouraging. Researchers are optimistic that LCL768 could be notably effective against tumors resistant to standard treatments. Reduced ceramide levels are common in many cancers, and boosting these levels with compounds like LCL768 could represent a new class of therapies targeting tumor cell metabolism and stress systems.
“These findings represent a new frontier in cancer therapy,” a senior official stated. “We’re not only targeting cancer cells, we’re dismantling their internal infrastructure and exploiting a fundamental weakness in how those cells manage energy and stress. That could make this treatment useful for a range of cancers.”
The team is actively working to advance LCL768 into clinical trials, with the ultimate goal of providing a new lifeline for patients facing hard-to-treat cancers.”This research lays the foundation for developing a new class of anti-cancer agents that exploit mitochondrial vulnerability,” a researcher concluded. “We are exploring how to optimize this approach for clinical use so that LCL768 or drugs like it could offer a safe, effective option for cancer patients who have few available treatments.”
The study, titled “Ceramide-Induced Metabolic Stress Depletes Fumarate and Drives Mitophagy to Mediate Tumor Suppression,” was published in Cancer Research on September 2, 2025 (DOI: 10.1158/0008-5472.CAN-24-4042). The research was supported by grants from the National Institutes of Health’s National cancer Institute (R01CA214461,R01CA285926,P01CA203628) and National Institute of Dental and Craniofacial Research (R01DE016572).